- |||||||||| Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica, Crixivan (indinavir sulfate) / Merck (MSD), Isentress (raltegravir) / Merck (MSD)
Journal: Evaluation of inhibition effect and interaction mechanism of antiviral drugs on main protease of novel coronavirus: Molecular docking and molecular dynamics studies. (Pubmed Central) - Oct 19, 2024
The interaction mechanism between antiviral drugs and main protease was analyzed in detail by calculating the root mean square displacement (RMSD), root mean square fluctuation (RMSF) and interaction residues properties. The results showed that the six drugs with high flexibility (Remdesivir, Simnotrelvir, Sofosbuvir, Ledipasvir, Indinavir and Raltegravir) had strong binding strength with 3CLpro, and the last four antiviral drugs can be used as potential candidates for main protease inhibitors.
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Review, Journal: Pre- and Post-Exposure Prophylaxis for HIV in Patients Taking Anti-Seizure Medications. (Pubmed Central) - Sep 23, 2024
This narrative review aims to be a resource for all clinicians prescribing ASMs so that they can create a welcoming environment to enable successful treatment of seizures and reduce the risk of HIV infection in people at risk. In addition, we highlight knowledge gaps and areas of unmet need that can be addressed with future studies.
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Journal: Specialty pharmacy interventions benefit patients receiving HIV post-exposure prophylaxis. (Pubmed Central) - Sep 15, 2024
PEP medications are expensive and time sensitive and can require clinical interventions and specific patient counseling. This study indicates that specialty pharmacies can provide and ensure access to care in the areas of financial assistance, patient counseling, and clinical interventions.
- |||||||||| Selzentry (maraviroc) / ViiV Healthcare, Intelence (etravirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Journal: Antiretroviral (ARV) Properties Dictate Long-Acting Release and Tissue Partitioning Behaviors in Multidrug Subcutaneous Implants. (Pubmed Central) - Sep 4, 2024
In mice, subcutaneous electrospun fiber implants exhibit burst release of the more hydrophilic drugs maraviroc (MVC) and raltegravir (RAL), which could be reduced via simple prewash treatments of the implants...However, end-point drug tissue concentrations show that the most hydrophobic drug etravirine (ETR) remains in high concentrations within the implant and in local skin tissue biopsies...Further, we find that the properties of ETR enable significant drug quantities within the tissues most relevant to HIV protection. Evidence from this work emphasizes the need for a greater focus on drug properties and prodrug strategies to enable relevant, extended, and targeted drug release.
- |||||||||| Mycobutin (rifabutin) / Pfizer, Lupin, raltegravir / Generic mfg.
Trial completion: Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients (clinicaltrials.gov) - Aug 28, 2024
P4, N=10, Completed,
Collectively, results of this study demonstrate poor and variable specific activity of different rUGTs (per pmol protein), as determined by pnAF values, which should be considered in fgluc scaling. Unknown status --> Completed
- |||||||||| Isentress (raltegravir) / Merck (MSD)
Journal: Pretreatment HIV-1 Resistance in Argentina: results from the second surveillance study following WHO guidelines (2019). (Pubmed Central) - Aug 9, 2024
This study generates the framework of evidence that supports the use of schemes based on high genetic barrier integrase inhibitors such as DTG as the first line of treatment and the need for the use of resistance test prior to prescribing schemes based on non-nucleoside inhibitors of reverse transcriptase. We report for the first time the presence of a natural polymorphism associated with the most prevalent viral recombinant form in Argentina that could have an impact on first-generation integrase inhibitors such as raltegravir.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
What Leads to Acquired Perforating Dermatosis? (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3274;
Experts estimate the incidence at 2.53 cases per 100,000 individuals annually. APD starts as 2
- |||||||||| Retrospective data, Journal: Antiretroviral therapy among people with HIV with comorbidities in the United States: a retrospective cohort study. (Pubmed Central) - Jun 24, 2024
The most commonly used anchor agents, 62.6%, were integrase strand transfer inhibitors (INSTIs): dolutegravir (30.4%), elvitegravir (24.2%), and raltegravir (7.3%)...From our analyses, ART prescribing did not appear to vary with the presence of comorbidities and potential medication contraindications. ART regimens may have comparable efficacy profiles; however, selection should be guided by each patient's comorbidities to prevent potential comedication drug toxicities.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
Trial completion date, Trial primary completion date: Pharmacokinetics Distribution of Raltegravir by PET/MR (clinicaltrials.gov) - Jun 18, 2024
P1, N=10, Recruiting,
ART regimens may have comparable efficacy profiles; however, selection should be guided by each patient's comorbidities to prevent potential comedication drug toxicities. Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| Integrase inhibitor (INSTI) use and outcomes among children living with HIV in Latin America & the Caribbean (Poster board: 131) - May 2, 2024 - Abstract #AIDS2024AIDS_1456;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Specific clusters of non-integrase mutations emerge during raltegravir and dolutegravir selection (Poster board: 136) - May 2, 2024 - Abstract #AIDS2024AIDS_1142;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| CCR5?32/?32 Allogeneic hematopoietic stem cell graft: time to analytical antiretroviral interruption? (Poster board: 144) - May 2, 2024 - Abstract #AIDS2024AIDS_1125;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Bictegravir and Dolutegravir modify leukocyte and endothelial cell adhesion molecules (Poster board: 035) - May 2, 2024 - Abstract #AIDS2024AIDS_1092;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, bictegravir (GS-9883) / Gilead
Maternal and fetal outcomes in mice treated with INSTIs including bictegravir and cabotegravir (Poster board: 034) - May 2, 2024 - Abstract #AIDS2024AIDS_1083;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
Journal: Structural rearrangements in the nucleus localize latent HIV proviruses to a perinucleolar compartment supportive of reactivation. (Pubmed Central) - Apr 26, 2024
The localization of proviruses to the PNC was blocked by integrase inhibitor Raltegravir, suggesting it was due to chromosomal rearrangements...HIV DNA in latently infected memory T cells from patients also accumulated in the PNC and showed identical patterns of nuclear rearrangements after cellular reactivation. Thus, in contrast to transformed cells where proviruses are found primarily at the nuclear periphery, in primary memory T cells, the nuclear architecture undergoes rearrangements that shape the transcriptional silencing and reactivation of proviral HIV.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
Review, Journal: Cerebrospinal fluid viral escape in HIV patients on antiretroviral therapy: A systematic review of reported cases. (Pubmed Central) - Apr 9, 2024
Over 36 ART regimens were employed, with a focus on ART intensification; almost one-third of the regimens contained Raltegravir (integrase strand transfer inhibitor)...When neuropsychological symptoms manifest in PLHIV, monitoring for CSF viral escape is essential, regardless of plasma viral suppression. Personalised treatment strategies, particularly ART intensification, are strongly advised for optimising treatment outcomes in PLHIV diagnosed with CSF HIV escape.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Emerging Integrase Resistance in the Perinatal Virtual Clinic: The Need for Protease Inhibitors (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_1329;
A second suppressed on nevirapine/3TC/ABC for 11 years simplified to DTG/3TC/ABC but failed 4 years later with an R263RK (intermediate DTG-R)...INSTI resistance is emerging in CALWHIV, most commonly in highly treatment experienced individuals from L/MIC. This highlights the global need for access to DRV/r, TXF and novel classes, including formulations for children <35kg.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
Outcomes Following Prenatal Exposure to Raltegravir: A Multi-Cohort European Study (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_1257;
This highlights the global need for access to DRV/r, TXF and novel classes, including formulations for children <35kg. The birth defect rate in EPPICC is consistent with and contributes to the current evidence-base on safety of periconception RAL use.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
HIV, Not Integrase Inhibitor-Based ART, Modifies Gut Microbiota Composition in MSM (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_1144;
In this study not confounded by sexual orientation, HIV and immune status significantly affected gut microbiota composition. However, we found no evidence to suggest that INSTI-based ART negatively influences gut microbiota composition.
- |||||||||| Isentress (raltegravir) / Merck (MSD), Istodax (romidepsin) / Astellas, BMS
Effective Elimination of HIV-1 Infected CD4+ T-Cells by NKG2C+ 'Memory-Like' NK Mediated by Trail (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_1056;
Finally, impact of anti-TRAIL, anti-NKG2C and anti-NKG2D or isotypic mAbs in NK cell-mediated elimination of p24+ HIV-1 infected CD4+ T cells from PLWH was tested in the presence of Romidepsin and Raltegravir.CD56dim and CD56- CD16+ NK cells from PLWH exposed to nano-PIC DC displayed increased levels of TRAIL compared to cells stimulated with control nano DC (p=0.0039). In conclusion, cytotoxic function of memory-like NKG2C+ CD57- NK cells associated with good functional elimination of HIV-1 reservoir CD4+ T cells is mediated by TRAIL.
- |||||||||| Efficacy and Safety of BLV 2 or 10 mg for 96 Weeks in CHD Including in 2 Patients With HIV/HBV/HDV (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_882;
P3
In conclusion, cytotoxic function of memory-like NKG2C+ CD57- NK cells associated with good functional elimination of HIV-1 reservoir CD4+ T cells is mediated by TRAIL. Background: Bulevirtide (BLV) is a first-in-class, entry inhibitor, approved in the EU for the treatment of chronic hepatitis D. Limited data exists on the safety and efficacy of BLV in HIV/HBV/HDV coinfection...At baseline, Patient 1 (Arm B) was age 39 years, HCV ab neg, HIV viral load (VL) undetectable, CD4 786/mm
- |||||||||| Associations Between Antiretroviral Therapy and Cardiovascular Events in People With Treated HIV (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_850;
The distribution of ART regimens was 45% INSTI- (14% raltegravir, 40% elvitegravir, 30% dolutegravir, and 16% bictegravir), 39% NNRTI-, and 16% PI-based regimen. In this large-scale study using U.S. claims databases, PI-based and INSTI-based regimens were associated with higher risk of MACE compared to NNRTI-based regimens after ART initiation, and the pattern of association between INSTIs and PIs with excess risk of MACE was similar.
- |||||||||| Isentress (raltegravir) / Merck (MSD)
Impact of Raltegravir Intensification on the Gut Microbiota of People With Chronic HIV-1 Infection (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_830;
In this large-scale study using U.S. claims databases, PI-based and INSTI-based regimens were associated with higher risk of MACE compared to NNRTI-based regimens after ART initiation, and the pattern of association between INSTIs and PIs with excess risk of MACE was similar. RAL intensification of PI/r or NNRTI-based regimens is associated with reduced immune activation and senescence in CD8+ T-cells, coupled with minor changes in the gut microbiome composition.
- |||||||||| First Trimester Exposure to Newer Antiretroviral Agents and Congenital Anomalies in a US Cohort (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_769;
The odds of congenital anomalies among infants with first trimester exposure to newer ARVs did not differ substantially from that among infants unexposed to these specific ARVs. However, modest effects cannot be ruled out, highlighting the need for continued evaluation of these associations in larger populations.
|
